| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 7 analysts have evaluated United Therapeutics (NASDAQ:UTHR), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 1 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $311.14, accompanied by a high estimate of $400.00 and a low estimate of $215.00. Surpassing the previous average price target of $299.00, the current average has increased by 4.06%.
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Hartaj Singh | Oppenheimer | Raises | Outperform | $400.00 | $375.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | - |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $325.00 | $309.00 |
| Liana Moussatos | Wedbush | Maintains | Outperform | $308.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | - |
| Chris Shibutani | Goldman Sachs | Raises | Neutral | $215.00 | $213.00 |
| Roanna Ruiz | Leerink Partners | Announces | Outperform | $330.00 | - |
To gain a panoramic view of United Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on United Therapeutics analyst ratings.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 25.07%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 35.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): United Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.71%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): United Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 3.06%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: UTHR
